Skip to content
Evrysdi(risdiplam)
Evrysdi (risdiplam) is a small molecule pharmaceutical. Risdiplam was first approved as Evrysdi on 2020-08-07. It has been approved in Europe to treat spinal muscular atrophy.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Evrysdi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Risdiplam
Tradename
Company
Number
Date
Products
EVRYSDIGenentechN-213535 RX2020-08-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
evrysdiNew Drug Application2020-09-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
RISDIPLAM, EVRYSDI, GENENTECH INC
2029-05-27ODE-400
2027-08-07ODE-334
2025-08-07NCE
2025-05-27NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Risdiplam, Evrysdi, Genentech Inc
115344442038-10-04U-1943
99697542035-05-11DS, DPU-1943
95869552033-02-08DS, DP
ATC Codes
M: Musculo-skeletal system drugs
— M09: Other drugs for disorders of the musculo-skeletal system in atc
— M09A: Other drugs for disorders of the musculo-skeletal system in atc
— M09AX: Other drugs for disorders of the musculo-skeletal system in atc
— M09AX10: Risdiplam
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinal muscular atrophyD009134EFO_0008525G12.14532213
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRISDIPLAM
INNrisdiplam
Description
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease.
Classification
Small molecule
Drug classsurvival motor neurin SMN1 and SMN2 splicing modulators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1
Identifiers
PDB—
CAS-ID1825352-65-5
RxCUI—
ChEMBL IDCHEMBL4297528
ChEBI ID—
PubChem CID118513932
DrugBankDB15305
UNII ID76RS4S2ET1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Evrysdi - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 479 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,101 adverse events reported
View more details